• Home
  • About
    • Our Approach
    • Guiding Principles
    • Leadership
    • Board of Directors
  • Technology
    • Platform
    • Product Engine
  • Pipeline
    • Pipeline
    • Clinical Candidates
  • Scientific Posters and Publications
  • Our Purpose
    • Ophthalmic Diseases
    • Pulmonary Diseases
    • Cardiology Diseases
  • Investors
  • Careers
    • Join our Team
    • Living our Guiding Principles
    • 4Diversity
    • What We Offer
    • Open Positions
  • Contact
  • Search
  • Menu Menu
  • View in Smaller Font
  • Reset to Default Font
  • View in Larger Font

Patient-Focused

Genetic Medicines with Curative Intent

Our Commitment to Patients

The definition of “advocate” is “to support a cause or proposal.” We believe that truly advocating for patients and families requires much more than “support.” It requires commitment, dedication, compassion and listening to ensure we are continually doing what is right for patients, their families and the greater community. We seek to inspire and lift up the advocates who work tirelessly to shine a light on debilitating diseases and conditions.

At 4DMT, our priority is to weave the patient perspective into the fabric of our work and daily activities. We believe in the importance of collaborating closely with patients, their families, patient advocacy organizations, physicians, researchers and regulatory authorities to educate on the work we are doing. We seek to advance our overall understanding of the diseases we treat, including the unmet patient needs that exist for each disease.

Ophthalmological Diseases

Wet Age-Related Macular Degeneration (Wet AMD)

Neovascular age-related macular degeneration (wet AMD) is a type of age-related macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. As a result, CNV causes swelling of and fluid retention in the retina, bleeding and scarring, and causes blurry vision and reduced ability to see small details. The ongoing leaking of the abnormal blood vessels is stimulated by vascular endothelial growth factor otherwise known as VEGF. This process distorts and can potentially destroy central vision and may progress to blindness without treatment. Wet AMD is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks.

Diabetic Macular Edema (DME)

People who have type 1 or type 2 diabetes may develop a complication called diabetic retinopathy or damage to the small blood vessels of the eye’s retina that can lead to vision loss. Diabetic macular edema (DME), which is associated with diabetic retinopathy and progresses faster, occurs when fluid from these damaged blood vessels leaks into the macula — an area in the center of the retina that helps us see objects directly ahead of us — which causes swelling of the retina and is also associated with vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks.

About 4D-150 for the treatment of wet AMD & DME

Ophthalmology Clinical Trials

4D-150 is being evaluated in the currently-enrolling PRISM clinical trial, a Phase 1/2 dose-escalation and randomized, controlled, masked expansion study of intravitreal 4D-150 in adults with wet AMD. The primary endpoints of the study are safety and tolerability. Secondary endpoints include the number of supplemental aflibercept injections over 52 weeks, change from baseline in best corrected visual acuity (BCVA) over time and central subfield thickness (CST) measured by SD-OCT.

ClinicalTrials.gov

4D-150 will be evaluated in the SPECTRA clinical trial, a Phase 2 randomized, active-controlled, double-masked study of intravitreal 4D-150 genetic medicine in adults with DME. The primary endpoint of this study is the annualized number of aflibercept injections in the study eye. Secondary endpoints include change from baseline in BCVA, CST and percentage of subjects with improvement in diabetic retinopathy severity scale. Enrollment is anticipated to begin in Q3 2023.

Stay informed

Clinical Trial Email Sign Up

Register below to receive updates on our clinical trial programs and other patient advocacy initiatives.

"*" indicates required fields

Name*

Contact

Treating physicians, patients and caregivers interested in learning more about 4DMT’s investigational genetic therapies currently in clinical studies (trials) can find more information at

www.clinicaltrials.gov

If you are a patient or caregiver interested in one of our clinical trials, talk with your treating physician to see if you may be a candidate. For all other inquiries, please contact Patient Advocacy at

patientadvocacy@4DMT.com

View our compassionate use policy

Compassionate Use Policy

At 4DMT, we are committed to developing safe, effective and transformative therapies for patients with rare diseases and limited or no treatment options. We understand the importance of bringing these therapies to the broadest group of patients as quickly as possible. We believe that the best path to potential regulatory approval, and subsequent access for the greatest number of patients, is by executing our clinical studies (or trials) as efficiently as possible. Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory review and potential approval.

After careful deliberation, we have determined that at this point in time, we must focus our efforts on conducting our clinical trials as efficiently as possible.

Therefore, participation in 4DMT clinical trials is the only way for patients to gain access to 4DMT’s investigational therapies early in development. We will continually evaluate the possibility of compassionate use, “Right to Try” and other expanded access programs.

Investigational therapies have not yet been approved by FDA or other regulatory agencies. Furthermore, investigational therapies may or may not be effective in the treatment of a condition, and use of the product may cause unexpected serious side effects.

About 4DMT

Our 4DMT genetic medicine engine holds the potential to generate transformative therapies that have the power to improve patient lives, or even cure disease.

Navigation

  • Home
  • About
    • Our Approach
    • Guiding Principles
    • Leadership
    • Board of Directors
  • Technology
    • Platform
    • Product Engine
  • Pipeline
    • Pipeline
    • Clinical Candidates
  • Scientific Posters and Publications
  • Our Purpose
    • Ophthalmic Diseases
    • Pulmonary Diseases
    • Cardiology Diseases
  • Investors
  • Careers
    • Join our Team
    • Living our Guiding Principles
    • 4Diversity
    • What We Offer
    • Open Positions
  • Contact

Location

5858 Horton St. Suite 455
Emeryville, CA 94608

(510) 505-2680
info@4dmt.com

© 2023 4D Molecular Therapeutics. All rights reserved.

  • Contact
  • Privacy Policy
  • Site Terms
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only